BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 336 filers reported holding BIO-TECHNE CORP in Q3 2019. The put-call ratio across all filers is 5.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,252 | -47.3% | 797 | -36.8% | 0.01% | -50.0% |
| Q2 2023 | $102,936 | +4.8% | 1,261 | -4.8% | 0.01% | 0.0% |
| Q1 2023 | $98,228 | -23.8% | 1,324 | -14.9% | 0.01% | -33.3% |
| Q4 2022 | $128,961 | +7.5% | 1,556 | +267.0% | 0.02% | -6.2% |
| Q3 2022 | $120,000 | +4.3% | 424 | +28.1% | 0.02% | +6.7% |
| Q2 2022 | $115,000 | -26.8% | 331 | -8.8% | 0.02% | -21.1% |
| Q1 2022 | $157,000 | -6.5% | 363 | +12.0% | 0.02% | -5.0% |
| Q4 2021 | $168,000 | +50.0% | 324 | +40.3% | 0.02% | +25.0% |
| Q3 2021 | $112,000 | +23.1% | 231 | +14.4% | 0.02% | +23.1% |
| Q2 2021 | $91,000 | +8.3% | 202 | -8.2% | 0.01% | -7.1% |
| Q1 2021 | $84,000 | +33.3% | 220 | +11.7% | 0.01% | +16.7% |
| Q4 2020 | $63,000 | +31.2% | 197 | +2.1% | 0.01% | +20.0% |
| Q3 2020 | $48,000 | -65.7% | 193 | -63.6% | 0.01% | -67.7% |
| Q2 2020 | $140,000 | +225.6% | 530 | +131.4% | 0.03% | +342.9% |
| Q1 2020 | $43,000 | +377.8% | 229 | +387.2% | 0.01% | +600.0% |
| Q4 2019 | $9,000 | +12.5% | 47 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $8,000 | -85.7% | 47 | -83.4% | 0.00% | -88.9% |
| Q2 2019 | $56,000 | +3.7% | 283 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $54,000 | +800.0% | 283 | +502.1% | 0.01% | +350.0% |
| Q4 2018 | $6,000 | -25.0% | 47 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $8,000 | +33.3% | 47 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $6,000 | 0.0% | 47 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $6,000 | +20.0% | 47 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $5,000 | -58.3% | 47 | -59.5% | 0.00% | -60.0% |
| Q3 2017 | $12,000 | +20.0% | 116 | +16.0% | 0.01% | +25.0% |
| Q2 2017 | $10,000 | +25.0% | 100 | +20.5% | 0.00% | 0.0% |
| Q1 2017 | $8,000 | 0.0% | 83 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $8,000 | 0.0% | 83 | 0.0% | 0.00% | -20.0% |
| Q3 2016 | $8,000 | 0.0% | 83 | 0.0% | 0.01% | -16.7% |
| Q2 2016 | $8,000 | +14.3% | 83 | +10.7% | 0.01% | +20.0% |
| Q1 2016 | $7,000 | +16.7% | 75 | 0.0% | 0.01% | +25.0% |
| Q4 2015 | $6,000 | -86.4% | 75 | -84.7% | 0.00% | -86.7% |
| Q3 2015 | $44,000 | -8.3% | 490 | -2.0% | 0.03% | -3.2% |
| Q2 2015 | $48,000 | – | 500 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |